Drug intelligence / Profile preview

HTX-009

Development stage: Unknown
Lead developer: Heron Therapeutics
Modality: Small Molecules
Administration: Local Infiltration

Overview

HTX-009 is an extended-release formulation of meloxicam designed for local administration into surgical sites to prevent postoperative pain. It is formulated using a proprietary tri[ethylene glycol] based poly[orthoester] polymer delivery system with dimethyl sulfoxide, glycerol triacetate, and maleic acid excipients. The drug works as a COX-2 inhibitor, targeting cyclooxygenase-2 enzymes that play a role in inflammation and pain.

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on HTX-009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HTX-009.

Explore the full profile